SviCas3 Gene Editing via Type I-B CRISPR-Cas Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene editing tools based on class 2 CRISPR-Cas systems, such as those using Cas9, have limitations like large molecular weights and off-target effects, making them unsuitable for efficient editing of prokaryotic and eukaryotic genomes.
Innovation Solution
A gene editing method utilizing a Cas3 expression vector and a gene editing vector based on the type I-B CRISPR-Cas system from Streptomyces virginiae IBL14, which enables specific DNA cleavage guided by crRNA or t-DNA, allowing for efficient editing of both prokaryotic and eukaryotic genomes without off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If class 2 CRISPR-Cas systems (Cas9, Cpfl) are used for gene editing, then gene editing capability is achieved, but molecular weight is large and off-target effects occur
Solution Approach 1:
The patent segments the CRISPR-Cas system by selecting only the essential Cas3 protein from the type I-B system, separating it from the complex multi-protein assemblies of class 2 systems. This segmentation achieves gene editing capability with a smaller, more manageable molecular weight component.
Solution Approach 2:
The patent extracts the core functional element (Cas3 protein) from the type I-B CRISPR-Cas system, taking out the essential gene editing capability while leaving behind the unnecessary complexity and larger molecular weight components found in class 2 systems.
2Reliability
If class 2 CRISPR-Cas systems (Cas9, Cpfl) are used for gene editing, then gene editing capability is achieved, but off-target effects occur
Solution Approach 1:
The patent applies local quality by optimizing the guide RNA design and Cas3 protein characteristics to enhance specificity at the target site. The system achieves high precision gene editing by improving the local matching conditions between guide RNA and target DNA, thereby eliminating off-target effects while maintaining editing capability.
Solution Approach 2:
The patent incorporates feedback mechanisms through the design of the CRISPR-Cas3 system where the guide RNA and Cas3 protein work together with high specificity. The system provides inherent feedback through precise base pairing requirements and controlled cleavage activity, ensuring that editing occurs only at the intended target location and preventing off-target effects.
3Adaptability or versatility
If type I CRISPR-Cas systems are discovered, then diversity of CRISPR systems is increased, but application to gene editing is not reported
Solution Approach 1:
The patent demonstrates universality by showing that the Cas3 protein from type I-B CRISPR-Cas system can perform gene editing functions previously only associated with class 2 systems. This multi-functionality bridges the gap between system diversity and practical application, enabling type I systems to be used for gene editing in various organisms.
Solution Approach 2:
The patent applies parameter changes by optimizing the Cas3 protein expression conditions, guide RNA design parameters, and delivery methods to make type I CRISPR-Cas systems suitable for gene editing applications. These parameter adjustments transform the theoretical diversity into practical ease of manufacture and application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a novel, error-free, and efficient gene editing system with SviCas3, which is superior to commercial Cas9 systems due to its smaller molecular weight and precise DNA targeting capabilities, enabling rapid and scarless modifications across various biological genomes.
Implementation Method 1
the protein SviCas3 can perform DNA cleavage by crRNA guiding or by t-DNA localization
Data Source
Figure 1(A)~2(B)
Figure 3
AI summary
A novel gene editing system developed based on the gene cas3 in the type I-B CRISPR-Cas system in the chromosome of Streptomyces virginiae IBL14 enables the gene editing of a type I CRISPR-Cas system on biological cell genomes for the first time. In the system, Cas3 can specifically cleave a DNA fragment of interest guided by crRNA or t-DNA. The new approach can be applied to rapid, simple and correct genome editing of prokaryotic and eukaryotic cells, which provides novel supplements and selections for the commercialized gene editing system developed based on Cas9 in type II.